
|Articles|April 1, 2003
Imiquimod Benefits Kids Off-Label
Bal Harbour, Fla. - The use of topically applied immune response modifier imiquimod (Aldara) goes beyond its FDA-approved application for the treatment of genital and perianal warts.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














